At seven in the morning, a hospital pharmacy technician checks a shelf against a screen. A ward needs a particular infusion by noon. Records say two packs; the shelf says one. Somewhere nearby, another team may have a box to spare without knowing anyone needs it. Repeat that moment across scores of acute trusts, each running its own pharmacy system, and the problem NHS England now wants to address comes into focus.
The agency has opened a pre-market engagement for secondary care medicines data, with a total value of £6.75 million. The notice describes capability and tooling to process data from hospital pharmacy systems, along with licensing and implementation support. Two products are named. The first is a reporting function for trusts, backed by a national dataset on stock position and daily issuance of medicines. The second is a tool that compares what trusts pay with the prices set out in the national procurement framework. Engagement closes on 1 November 2026, and contracts are expected to run from April 2027 to March 2028, with extensions available to March 2029.
Medicines are among the largest non-pay costs in hospital care, and spending on them runs into billions of pounds each year. Yet the national picture of what sits on shelves, and how quickly it leaves them, has been assembled largely by phone calls and local spreadsheets. Daily issuance data changes that. It is a demand signal, and demand signals are what supply planners have long lacked. If a shortage of a common antibiotic is building in one region, a national dataset can show it before wards start improvising. Stock held in surplus at one trust can be identified and offered to another. Pharmacy teams, who already spend considerable time managing supply fragility, stand to gain hours back.
The price comparison tool deserves equal attention. National frameworks exist to secure favourable terms for the whole system, but a framework price is only useful if trusts can see whether they are actually paying it. Variation between what is agreed centrally and what is invoiced locally has been hard to detect at scale. A tool that makes it visible gives finance directors and chief pharmacists a factual basis for challenge, and gives the centre evidence for negotiation. At a time when trusts are expected to deliver productivity gains without reducing activity, savings found in procurement are among the least painful available.
The size of the commitment suits the task. Set against the NHS budget, £6.75 million is modest, and a defined purpose, a short initial term and options to extend leave room to learn as the work proceeds. Consulting the market first is sensible too. Health-tech firms with experience of joining up data across varied hospital systems will have practical views on what can be built, and the engagement process lets those views shape the specification. The same month brought news of an open framework worth up to £838 million for GP IT, which suggests a steady, coordinated investment in the digital foundations of care.
Security will determine how far that confidence is justified. Pharmacy issuance data is largely operational, yet it sits close to patient records, and any dataset that aggregates activity from across the country becomes an attractive target. The NHS has recent experience of what disruption looks like. A cyber attack on a pathology services provider in 2024 delayed procedures and tests across several London trusts, and the lesson was plain: a failure in one supplier can ripple through many hospitals at once. A national dataset therefore needs strong supplier assurance, tight access controls and clear audit trails from the first day of design. Trusts already work to the Data Security and Protection Toolkit, and new suppliers should be held to equivalent standards as a condition of contract.
Governance matters for public confidence as much as for resilience. Clear rules on who can see the data, how quality is checked and who owns the outputs will help trusts contribute willingly. Data should return to them in a form they can act on, without adding reporting burden to stretched pharmacy departments. Life sciences companies will watch closely, because a national view of hospital usage will inform later conversations on pricing and supply. Transparent handling of that information will help those conversations stay constructive.
Patients will never see any of this. They will notice only what does not happen: the cancelled infusion, the last-minute substitution, the delayed discharge while a medicine is traced. If the programme works, the pharmacy technician at seven in the morning will look at a screen that reflects what the whole system knows, held securely and used well, and the day will begin with one fewer problem to solve.
